Chongqing Conquer Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation finerenone tablets (specification: 10 mg, produced by Chongqing Kangkeer Pharmaceutical Co., Ltd.) and the reference preparation finerenone tablets (Kerendia®, specification: 10 mg, produced by Bayer AG) in healthy participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study: to evaluate the safety of the test preparation finerenone tablets (specification: 10 mg) and the reference preparation finerenone tablets (Kerendia®, specification: 10 mg) in healthy participants.

Main purpose: Using dapagliflozin tablets [Specification: 10 mg] produced by Chongqing Kangkeer Pharmaceutical Co., Ltd. as the test preparation, and using dapagliflozin tablets [trade name: Andatang, specification: 10 mg] certified by AstraZeneca AB as the reference preparation, a human bioequivalence test was conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of tadalafil tablets (test preparation, specification: 20 mg) developed by Chongqing Kangkeer Pharmaceutical Co., Ltd. and tadalafil tablets (reference preparation, trade name: Cialis®, specification: 20 mg) licensed by Eli Lilly Nederland B.V. and produced by Lilly del Caribe, Inc., after a single oral dose in healthy Chinese adult male subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of the test preparation (specification: 20 mg) and reference preparation (trade name: Cialis®, specification: 20 mg) of tadalafil tablets in healthy Chinese adult male subjects.